RORγt+ innate lymphoid cells promote lymph node metastasis of breast cancers

Sheeba Irshad, Fabian Flores-Borja, Katherine Lawler, James Monypenny, Rachel Evans, Victoria Male, Peter Gordon, Anthony Cheung, Patrycja Gazinska, Farzana Noor, Felix Wong, Anita Grigoriadis, Gilbert O. Fruhwirth, Paul R. Barber, Natalie Woodman, Dominic Patel, Manuel Rodriguez-Justo, Julie Owen, Stewart G. Martin, E. Pinder SarahE. Gillett Cheryl, Simon P. Poland, Simon Ameer-Beg, Frank McCaughan, Leo M. Carlin, Uzma Hasan, David R. Withers, Peter Lane, Borivoj Vojnovic, Sergio A. Quezada, Paul Ellis, Andrew N J Tutt, Tony Ng*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

98 Citations (Scopus)
225 Downloads (Pure)

Abstract

Cancer cells tend to metastasize first to tumor-draining lymph nodes, but the mechanisms mediating cancer cell invasion into the lymphatic vasculature remain little understood. Here, we show that in the human breast tumor microenvironment (TME), the presence of increased numbers of RORgt group 3 innate lymphoid cells (ILC3) correlates with an increased likelihood of lymph node metastasis. In a preclinical mouse model of breast cancer, CCL21-mediated recruitment of ILC3 to tumors stimulated the production of the CXCL13 by TME stromal cells, which in turn promoted ILC3 stromal interactions and production of the cancer cell motile factor RANKL. Depleting ILC3 or neutralizing CCL21, CXCL13, or RANKL was sufficient to decrease lymph node metastasis. Our findings establish a role for RORgtILC3 in promoting lymphatic metastasis by modulating the local chemokine milieu of cancer cells in the TME.

Original languageEnglish
Pages (from-to)1083-1096
Number of pages14
JournalCancer Research
Volume77
Issue number5
Early online date12 Jan 2017
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • ILC3
  • BREAST CANCER
  • CHEMOKINES
  • METASTASIS
  • Lymph Nodes

Fingerprint

Dive into the research topics of 'RORγt+ innate lymphoid cells promote lymph node metastasis of breast cancers'. Together they form a unique fingerprint.

Cite this